PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride

15 Nov 2017

• By Emily Hayes

Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.

The third quarter marked a turning point for Merck & Co. Inc.'s PD-1 inhibitor Keytruda, which hit the $1bn sales mark and finally started closing in on Bristol-Myers Squibb Co.'s market-leading competitor Opdivo, but with many catalysts around the corner for the most valuable indication of lung cancer, investors are bracing for shakeups.

Opdivo's performance in the third quarter was better than expected as nivolumab brought in $1.3bn in sales, up by 38% from the same period in 2016 (see chart). That compares to $1.2bn (up by 42% from 2016) in the second quarter

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

28 Apr 2025

• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

28 Apr 2025

• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

25 Apr 2025

• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.